Sanofi India Declares Interim Dividend of Rs 75 Per Share with Record Date Set for November 5
Multinational pharmaceutical company Sanofi India Limited has announced an interim dividend of ₹75 per equity share of face value ₹10 each for the financial year 2026. The decision was approved by the company's Board of Directors during its meeting on October 29, 2026.
The payout reinforces Sanofi India’s track record of rewarding shareholders through healthy cash distributions. The company has established a consistent dividend distribution history, reflecting steady operating cash flows and disciplined capital allocation.
Key Dividend Dates and Eligibility
The company has set the timeline for determining shareholder eligibility for the interim dividend payout:
- Record Date: Thursday, November 5, 2026
- Ex-Dividend Date: Thursday, November 5, 2026
- Payout Amount: ₹75 per equity share (face value ₹10)
Shareholders whose names appear in the Register of Members or as beneficial owners in the records of the National Securities Depository Limited (NSDL) and Central Depository Services (India) Limited (CDSL) as of the close of business hours on November 5, 2026, will be eligible to receive the dividend. In line with statutory guidelines, dividend distributions will be subject to applicable Tax Deducted at Source (TDS) under prevailing income tax laws.
Strong Earnings Momentum Backs Payout
The dividend declaration coincided with the announcement of the unaudited financial results for the quarter ended September 30, 2026, which revealed strong profit expansion:
- Net Profit: Profit after tax grew 54% year-on-year to ₹116.7 crore, up from ₹76 crore in the corresponding period of the previous year.
- Revenue from Operations: Revenue rose 3.4% to ₹491.7 crore, compared to ₹475.4 crore in the September 2025 quarter.
- Profit Before Tax: PBT before exceptional items advanced 22% to ₹158 crore from ₹130 crore a year earlier.
- Operating Performance: Earnings Before Interest, Taxes, Depreciation, and Amortisation (EBITDA) rose 20.8% to ₹161 crore from ₹133 crore, with EBITDA margins widening to 32.8%.
- Exceptional Item: The company recognized a one-time personnel separation cost of ₹27.3 crore during the quarter.
Business Drivers and Market Position
Operating momentum during the quarter was anchored by Sanofi India’s diabetes portfolio, where its insulin segment recorded high single-digit growth. The company continues to maintain a leadership position with an estimated 55% market share in the diabetes injectable space, driven by established brands such as Lantus, Toujeo, and Apidra, alongside contributions from Soliqua.
Additionally, the company reported strong traction in its public sector institutional business through tenders for innovative analogue therapies, while export revenue also demonstrated double-digit growth. Overall operating expenses declined during the period, driven by favorable product mix and ongoing cost-efficiency measures.
